Clinical Trial Update: Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating ranibizumab for persistent diabetic neovascularization assessed by wide-field imaging in proliferative diabetic retinopathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Proliferative Diabetic Retinopathy

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Rush University Medical Center | Conditions: Proliferative Diabetic Retinopathy | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-11-06